Scientific deep-dive

Tirzepatide (Mounjaro, Zepbound) Muscle Loss: SURMOUNT-1 DXA Lean-Mass Evidence

Muscle loss on tirzepatide is real but proportional to weight lost, not unique to the drug. SURMOUNT-1 DXA (Look 2025): ~75% fat / ~25% lean — same split as placebo. Zepbound and Mounjaro FDA labels do NOT list muscle loss as an adverse reaction.

By Eli Marsden · Founding Editor
Editorially reviewed & fact-checked against primary sources · How we verify contentLast reviewed
14 min read·12 citations

The honest answer

Muscle loss on tirzepatide is real but PROPORTIONAL to weight lost, not unique to the drug. SURMOUNT-1 DXA (Look 2025) showed −21.3% body weight, −33.9% fat mass, −10.9% lean mass at Week 72 — roughly 75% fat, 25% lean. The placebo arm showed the same split. Neither the Zepbound nor Mounjaro FDA label lists muscle loss as an adverse reaction. Resistance training 2-3x/week plus adequate protein (about 1.2-1.5 g/kg a day is the published reference point for adults over 65; no GLP-1-specific target exists) is the protective intervention.

“Does tirzepatide cause muscle loss?” is one of the most-searched patient questions about Zepbound and Mounjaro therapy, and the honest answer is more nuanced than the viral TikTok framing suggests. Yes, a portion of weight lost on tirzepatide is lean tissue rather than fat — this is now well-documented in the SURMOUNT-1 DXA substudy[1] published in 2025. But the lean-tissue percentage of total weight loss is COMPARABLE to non-pharmacological rapid weight loss and to bariatric surgery, not a uniquely drug-induced phenomenon. The Zepbound and Mounjaro prescribing information do not list muscle loss, sarcopenia, or myopathy as labeled adverse reactions. What matters more than the drug choice is whether the patient is doing the two interventions with the strongest evidence for preserving muscle in a caloric deficit: resistance training 2-3 days per week and adequate protein.

At a glance

  • SURMOUNT-1 DXA substudy[1] (Look 2025, n=160): on tirzepatide, body weight fell 21.3%, fat mass fell 33.9%, and lean mass fell 10.9% at Week 72.
  • Of the weight lost, approximately 75% was fat mass and 25% was lean mass — on both tirzepatide AND placebo arms.
  • In post-hoc analyses by sex, age (under 50, 50-65, 65+), and tertiles of total weight lost, the 75/25 split stayed consistent across most subgroups.
  • Retatrutide body composition substudy[4] (Coskun 2025) explicitly concluded that the proportion of lean mass loss to weight loss was similar to other obesity treatments — consistent with tirzepatide and semaglutide.
  • Neither the Zepbound nor Mounjaro DailyMed prescribing information lists muscle loss, sarcopenia, or myopathy as a labeled adverse reaction.
  • The protective interventions: resistance training 2-3 days per week, enough protein (published reference points are 1.2-1.5 g/kg a day for healthy adults over 65 and up to 1.5 g/kg of ideal body weight after bariatric surgery, per the Mechanick 2025 review[11]), and avoiding overly aggressive rate of weight loss.

What “muscle loss on tirzepatide” actually means (DXA fat vs lean mass)

When someone loses weight — whether on tirzepatide, on semaglutide, after bariatric surgery, on a very-low-calorie diet, or in caloric restriction without any intervention — the weight that comes off is not pure body fat. It is a mix of fat mass and lean tissue, where “lean tissue” on a dual-energy X-ray absorptiometry (DXA) scan includes skeletal muscle, organ tissue, bone-attached connective tissue, and intracellular water in lean compartments. The classic body composition ratio for moderate-rate weight loss in mixed-age adults is roughly 75% fat mass and 25% lean mass. Faster weight loss tilts the ratio toward more lean tissue lost; slower weight loss with high protein and resistance training tilts it toward more fat.

Tirzepatide (Zepbound for obesity, Mounjaro for type 2 diabetes, both made by Eli Lilly) produced mean weight loss of 15.0%, 19.5% and 20.9% at the 5, 10 and 15 mg doses over 72 weeks in the SURMOUNT-1 pivotal trial[2], against 3.1% on placebo. The composition of that weight loss is the relevant clinical question, and the SURMOUNT-1 DXA substudy[1] is the primary peer-reviewed source.

The framing matters. “Tirzepatide causes muscle wasting” is misleading. “Tirzepatide produces large weight loss, and the composition of that weight loss follows the same physiology as any rapid weight loss — meaning a portion is lean tissue, and the percentage can be optimized with resistance training and protein” is the accurate version.

Does Mounjaro cause muscle loss?

Mounjaro is the same molecule, so the same answer applies. Mounjaro (tirzepatide) has no direct toxic action that targets and destroys muscle. What it does is produce substantial weight loss, a larger average reduction than is typically seen with semaglutide,[2] and whenever the body sheds weight that quickly it draws on both fat and lean tissue. That is the same pattern seen with very-low-calorie diets and with bariatric surgery: a consequence of the calorie deficit and the rate of loss, not something unique to GLP-1/GIP drugs.[11]

Because tirzepatide drives more total weight loss on average, there is simply more total tissue moving, which is one reason lean-mass preservation is worth taking seriously on Mounjaro. Mounjaro also blunts hunger strongly, which can quietly drop your protein and calorie intake below what muscle maintenance needs, so regular, protein-forward meals matter even when you are not hungry. Headlines like “Mounjaro melts muscle” overstate the case: the measured lean-mass losses in the SURMOUNT body-composition data were broadly proportional to the weight lost, with fat making up the larger share.[1][11]

What the SURMOUNT-1 body-composition substudy showed

Look and colleagues[1] published the SURMOUNT-1 DXA body composition substudy in Diabetes, Obesity and Metabolism in 2025. SURMOUNT-1 was the pivotal Phase 3 trial of tirzepatide in adults with obesity over 72 weeks. The DXA substudy enrolled 160 of the 2,539 main-trial participants (124 pooled tirzepatide, 36 placebo) and measured fat mass and lean mass at baseline and Week 72. The key results:

  • Total body weight reduction: −21.3% on tirzepatide vs −5.3% on placebo at Week 72 (p < 0.001).
  • Total fat mass reduction: −33.9% on tirzepatide vs −8.2% on placebo (p < 0.001).
  • Total lean mass reduction: −10.9% on tirzepatide vs −2.6% on placebo (p < 0.001).
  • Composition of weight lost: approximately 75% fat mass and 25% lean mass on BOTH tirzepatide and placebo arms — the standard body composition ratio for moderate-rate weight loss in healthy-physiology adults.
  • Subgroup consistency: in post-hoc analyses by sex (73% female cohort), age (less than 50, 50 to less than 65, 65 or older), and tertiles of total body weight reduction (15.3 kg or less, more than 15.3 to 25.9 kg, more than 25.9 kg), the 75/25 split remained consistent across most subgroups.

The placebo arm showing the same 75/25 fat-to-lean ratio is the critical observation. It supports the conclusion that the body composition split is NOT a tirzepatide-specific pharmacological effect but a generic consequence of the rate and total amount of weight lost. The drug is doing what any meaningful caloric deficit does, with the absolute magnitude of weight loss (driven by tirzepatide's appetite-suppression mechanism) being the differentiating factor.

Magnitude comparison

Composition of weight lost on tirzepatide (SURMOUNT-1 DXA substudy, Look 2025, Week 72). Roughly 75% of total weight lost was fat mass and 25% was lean tissue — the same 75/25 split was seen in the placebo arm, indicating the ratio reflects rate-of-weight-loss physiology rather than a tirzepatide-specific effect. Resistance training plus adequate protein can shift this ratio toward more fat and less lean.[1]

  • Fat mass reduction (% of starting fat mass)33.9 % ↓
    the desired body composition change
  • Total body weight reduction (% of starting weight)21.3 % ↓
    tirzepatide pooled doses, 72 weeks
  • Lean mass reduction (% of starting lean mass)10.9 % ↓
    ~25% of total weight lost was lean tissue — proportional, not abnormal
Composition of weight lost on tirzepatide (SURMOUNT-1 DXA substudy, Look 2025, Week 72). Roughly 75% of total weight lost was fat mass and 25% was lean tissue — the same 75/25 split was seen in the placebo arm, indicating the ratio reflects rate-of-weight-loss physiology rather than a tirzepatide-specific effect. Resistance training plus adequate protein can shift this ratio toward more fat and less lean.

How tirzepatide compares to retatrutide and semaglutide on lean mass

Cross-drug comparison gives the next layer of context. Coskun and colleagues[4] published the retatrutide body composition substudy in Lancet Diabetes & Endocrinology in 2025. Retatrutide is the triple-agonist (GIP/GLP-1/glucagon) successor to tirzepatide in Eli Lilly's pipeline. The Phase 2 substudy in adults with type 2 diabetes (n=189 enrolled, n=103 with paired baseline + Week 36 DXA) reported:

  • Retatrutide 8 mg pooled: 26.1% reduction in total fat mass at Week 36 (vs 4.5% on placebo, p < 0.0001).
  • Retatrutide 12 mg: 23.2% fat mass reduction.
  • Dulaglutide 1.5 mg comparator: 2.6% fat mass reduction (similar to placebo).
  • Authors' conclusion: “The proportion of lean mass loss to weight loss was similar to other obesity treatments. These findings could provide reassurance that a greater proportion of lean mass is not lost with retatrutide despite the overall increased weight loss.”

Semaglutide DXA data comes primarily from the STEP program. Wilding 2021 STEP-1[5] reported 14.9% total body weight loss at Week 68 in adults with overweight or obesity without diabetes. Wadden 2021 STEP-3[6] reported 16.0% body weight loss when semaglutide was combined with intensive behavioral therapy (compared with 5.7% on placebo). Published cross-trial DXA estimates for semaglutide land in the same 25-40% lean-tissue-of-TBWL range as tirzepatide, with the same caveat that the absolute kilograms of lean tissue lost depend on total weight loss.

The clinically important takeaway: tirzepatide, semaglutide, and retatrutide all appear to produce similar body composition SPLITS (roughly 75/25 fat to lean), with the differentiating factor being the TOTAL magnitude of weight loss each drug achieves. For our full head-to-head comparison, see the tirzepatide vs semaglutide head-to-head evidence review and the retatrutide vs tirzepatide head-to-head evidence.

How tirzepatide compares to bariatric surgery on lean mass

Bariatric surgery has historically produced the largest weight losses available outside of starvation protocols. Roux-en-Y gastric bypass and sleeve gastrectomy typically produce 25-35% total body weight loss at 12-24 months, with body composition substudies consistently reporting a 70-80% fat / 20-30% lean ratio of weight lost. Cava and colleagues[9] reviewed the evidence on muscle during weight loss in Advances in Nutrition and concluded that diet-induced weight loss reduces muscle mass without adversely affecting muscle strength, that high protein intake helps preserve lean and muscle mass, and that resistance exercise both preserves muscle and improves strength.

Stefanakis and colleagues[8] reviewed the impact of weight loss on fat-free mass, muscle, bone, and hematopoiesis in Metabolism in 2024 and reached the same conclusion: the lean tissue loss seen on tirzepatide and other GLP-1-based therapies is on the same magnitude as bariatric surgery and very-low-calorie diets at the equivalent total weight loss. The active mitigation strategies (resistance training, protein, slower rate of loss) are also the same across modalities.

For patients deciding between tirzepatide and bariatric surgery, muscle loss is NOT a meaningful differentiator. The decision rests on other factors: durability of weight loss, side effect profile, cost, surgical risk, and patient preference. Our bariatric surgery vs GLP-1 decision guide walks through the full comparison.

Resistance training during tirzepatide treatment — what the evidence shows

The single highest-evidence intervention for preserving lean mass during weight loss is resistance training. Murphy and Koehler[10] published a meta-analysis and meta-regression in Scandinavian Journal of Medicine & Science in Sports in 2022 examining the effect of energy deficiency on lean mass and strength gains from resistance training. The pooled finding: energy deficiency impairs lean mass gains from resistance training (effect size attenuated relative to energy balance) but does NOT impair strength gains — meaning patients can still get stronger in a caloric deficit, and resistance training still attenuates lean mass loss in a deficit relative to no training.

The practical translation for tirzepatide patients: resistance training will not allow you to gain meaningful muscle while in the 21% body weight deficit produced by tirzepatide 15 mg, but it WILL meaningfully reduce the proportion of weight lost that is lean tissue. The Murphy 2022 meta-regression suggests the magnitude of lean mass preservation is dose-dependent on training frequency and intensity, with 2-3 sessions per week of compound lifts at moderate-to-high effort producing the clearest signal.

Practical prescription, from the broader resistance-training evidence base referenced in our companion exercise pairing on a GLP-1 evidence review:

  • 2-3 resistance training sessions per week, 45-60 minutes per session.
  • 8-10 exercises targeting major muscle groups, prioritizing compound lifts: squat, hinge (deadlift or Romanian deadlift), horizontal push (dumbbell press or push-up), horizontal pull (row or pull-up), and carry (farmer carry or sled push).
  • 8-12 reps per set, 2-4 sets per exercise, with progressive overload week to week.
  • Cardio is helpful for cardiometabolic health but does not preserve muscle the way resistance training does. Combine both if possible; do not substitute cardio for resistance training if lean mass preservation is the goal.

A note on muscle-preserving drugs

Some research is exploring investigational drug combinations intended to preserve or build muscle during incretin-driven weight loss, for example pairing a GLP-1 or GLP-1/GIP drug with bimagrumab (an activin-receptor antibody) or other myostatin-pathway drugs being studied in trials. These are not FDA-approved for this purpose, their long-term safety and benefit are unproven, and they are not part of standard care. For now, the established way to protect muscle on Mounjaro or Zepbound remains adequate protein plus resistance training, not an additional drug.

Protein intake on tirzepatide — practical targets

No trial has set a protein target specific to GLP-1 therapy. The Mechanick 2025 review of strategies for minimizing muscle loss on incretin drugs[11] lists the published reference points and says intake should be adapted to each patient:

  • Baseline: the Recommended Dietary Allowance for healthy people is 0.8 g/kg body weight per day, and higher amounts (1.2-1.5 g/kg) have been recommended for healthy people older than 65[11].
  • Closest clinical analogs: after bariatric surgery, guidelines call for at least 60 g a day and up to 1.5 g/kg of ideal body weight; Joslin Diabetes Center guidance is 1.0-1.5 g/kg of adjusted body weight[11].
  • Higher intakes: in a 4-week trial of young men on a roughly 40% energy deficit with intense training six days a week, 2.4 g/kg a day gained more lean mass and lost more fat than 1.2 g/kg[12]. That is a training study, not a GLP-1 study.
  • Distribution: 3-4 meals per day with 25-40 g of protein each, hitting the per-meal threshold (~0.25-0.40 g/kg) for maximal muscle protein synthesis stimulation.

For a 75 kg adult, 1.2-1.5 g/kg works out to about 90-113 g of protein per day, distributed as 25-40 g per meal across 3-4 daily meals. The practical challenge on tirzepatide is meeting this target on a suppressed appetite. Many patients drop daily caloric intake by 30-50% on tirzepatide without explicitly tracking protein, ending up well short of that. Protein-first meal sequencing (eat protein before carbs and fats at each meal) helps when fullness comes early in a meal.

Our GLP-1 protein & macro calculator gives a personalized target. For specific food choices that hit the threshold dose efficiently, see our what to eat on a GLP-1 protein guide and the best protein powder for weight loss on a GLP-1 evidence review. For protein timing specifically, see the when to drink protein shakes for weight loss (female-focused evidence).

Why this matters more in perimenopausal and older patients

The clinical stakes of lean mass loss are highest in adults over 65 and in perimenopausal women. Older adults are already at risk of sarcopenia (age-related muscle loss starting in the fourth decade and accelerating after 60), fragility fractures, and loss of functional independence. Perimenopausal women face accelerated sarcopenia driven by estrogen decline, which impairs muscle protein synthesis independently of caloric intake or training.

Stefanakis and colleagues[8] note that advanced age and prefrailty may affect who is a suitable candidate for current and emerging obesity drugs, because of the associated sarcopenia risk. In practice that points to:

  • DXA monitoring is standard, not optional in adults over 65 and in perimenopausal women. Baseline DXA scan plus follow-up every 6 months to track lean mass and bone mineral density.
  • Structured resistance training is required rather than recommended. Working with a credentialed exercise physiologist or physical therapist for the first 4-12 weeks of training to establish safe form is reasonable.
  • Protein toward the upper end of published targets (1.2-1.5 g/kg body weight per day has been recommended for healthy people over 65[11]).
  • Slower rate of loss may be preferred. The 0.5-1.0% body weight per week target is appropriate; aggressive deficits producing 1.5-2% per week in older adults or perimenopausal women disproportionately remove lean tissue and bone.
  • Fall risk should be tracked. Lean mass loss plus weight loss can transiently impair balance.

What the Zepbound and Mounjaro FDA labels say about muscle loss

Neither the Zepbound (tirzepatide for obesity) nor the Mounjaro (tirzepatide for type 2 diabetes) DailyMed prescribing information lists muscle loss, sarcopenia, myopathy, or lean mass reduction as a labeled adverse reaction in Section 6 (Adverse Reactions). The body composition shifts during weight loss are characterized as a consequence of weight reduction rather than a direct drug pharmacological effect.

The Mounjaro DailyMed SetID is d2d7da5d-ad07-4228-955f-cf7e355c8cc0 and the Zepbound prescribing information is searchable via the DailyMed portal. The Mounjaro label's clinical-trial adverse reactions include nausea, diarrhea, vomiting, constipation, abdominal pain, dyspepsia, injection site reactions, fatigue, hypersensitivity reactions, eructation and gastroesophageal reflux disease. Hair loss is not among them: Mounjaro lists alopecia only in its postmarketing reports. The SURMOUNT-1 DXA substudy[1] is the primary peer-reviewed source clinicians reference for the magnitude of lean mass change during tirzepatide treatment, and that substudy is referenced in the broader prescribing-information narrative on body composition rather than as a labeled adverse event.

For the full FDA-label decoding, see our Mounjaro/Zepbound FDA prescribing information explained article.

What about tirzepatide withdrawal? SURMOUNT-4 evidence

Aronne and colleagues[3] published SURMOUNT-4 in JAMA in 2024. The trial enrolled adults who had achieved meaningful weight loss on tirzepatide during a 36-week open-label lead-in period, then randomized them to continued tirzepatide vs placebo for an additional 52 weeks. The continued-tirzepatide group lost an additional 5.5% of body weight; the placebo (withdrawal) group regained 14.0% of body weight, for a net 19.4 percentage-point difference between arms at Week 88.

The body composition implications: substantial weight regain after tirzepatide withdrawal, and the composition of regained weight in observational follow-up tends to be disproportionately fat mass rather than lean tissue. This is the standard pattern seen after any weight-loss intervention is stopped — regained weight rarely fully restores baseline lean tissue, especially without active resistance training. The implication is that active resistance training during AND after a tirzepatide cycle is the most important intervention for preserving body composition trajectory regardless of whether the drug is continued.

Practical takeaway

  • Muscle loss on tirzepatide is real but PROPORTIONAL to the rate and total amount of weight lost — not a uniquely pharmacological effect. Neither the Zepbound nor Mounjaro FDA label lists muscle loss as a labeled adverse reaction.
  • The SURMOUNT-1 DXA substudy[1] (the highest- quality body composition data on tirzepatide) showed roughly 75% of weight lost was fat mass and 25% was lean tissue at Week 72 — the SAME split was observed in the placebo arm, confirming the ratio reflects weight-loss physiology rather than a drug-specific effect.
  • Cross-drug comparison: retatrutide[4], semaglutide[5][6], and bariatric surgery all produce a similar fat-to-lean split (roughly 75/25). The differentiating factor between drugs is total magnitude of weight loss, not body composition quality.
  • Resistance training 2-3 days per week is the single highest- evidence protective intervention. Murphy 2022 meta-analysis[10] showed energy deficiency impairs lean mass gains but not strength gains — you can still get stronger in a deficit, and training still attenuates lean mass loss.
  • No GLP-1-specific protein target exists; published reference points run from 0.8 g/kg (RDA) to 1.2-1.5 g/kg for adults over 65 and up to 1.5 g/kg of ideal body weight after bariatric surgery[11]. Distribute across 3-4 meals of 25-40 g protein each.
  • DXA scan at baseline and every 6 months is the gold standard for tracking. BIA scales are the next-best home option. Tape measurements plus progress photos are the cheapest objective adjunct.
  • Adults over 65 and perimenopausal women should treat DXA monitoring and structured resistance training as standard, not optional. The clinical stakes of lean mass loss are highest in these populations.

Patients with cardiovascular disease, joint pathology, kidney disease, eating disorders, or other conditions limiting exertion or affecting protein metabolism should consult a clinician (and ideally a credentialed exercise physiologist or registered dietitian) before starting any new exercise or supplementation program. The SURMOUNT-1 DXA substudy[1] reports body composition data on tirzepatide in adults with obesity without type 2 diabetes; the SURPASS-3 MRI substudy[7] reports body fat distribution data on tirzepatide in adults with type 2 diabetes. Cross-population extrapolation between these cohorts is reasonable but not identical.

Further reading

Our reviews

Providers that offer tirzepatide

Telehealth providers we’ve reviewed. Each opens our full, independent review.

Also for this topic

For the muscle side: strength-training apps

Workout apps and coaching for the exercise side of your plan. Each opens our full, independent review.

We may earn a commission from featured partners. Learn more

See the full ranking →

Frequently Asked Questions

Tirzepatide (sold as Mounjaro for type 2 diabetes and Zepbound for weight management) produces lean tissue loss as part of overall weight loss, but the proportion is comparable to non-pharmacological rapid weight loss — not a unique drug effect. The SURMOUNT-1 DXA substudy (Look 2025, PMID 39996356) showed roughly 75% of weight lost was fat mass and 25% was lean tissue at 72 weeks, with the 5, 10, and 15 mg tirzepatide doses pooled. The placebo arm showed the same 75/25 ratio. Neither the Zepbound nor the Mounjaro FDA label lists muscle loss, sarcopenia, or myopathy as a labeled adverse reaction. The protective interventions are resistance training 2-3 days per week plus adequate protein (about 1.2-1.5 g/kg a day is the published reference point for adults over 65; no GLP-1-specific target exists).
In the SURMOUNT-1 DXA substudy (Look 2025, PMID 39996356), tirzepatide patients lost 21.3% of body weight, 33.9% of fat mass, and 10.9% of lean mass at Week 72. About 25% of the weight lost was lean tissue. A patient losing 20% of body weight on tirzepatide would expect roughly 5% of starting body weight as lean tissue loss and roughly 15% as fat mass loss — proportional to the rate and total amount of weight lost. The post-hoc subgroup analysis by sex, age (under 50, 50-65, 65+), and tertiles of total weight lost found the 75/25 split consistent across most subgroups.
Head-to-head DXA comparisons are limited, but the cross-trial data suggests both drugs produce a similar fat-to-lean ratio of weight lost (roughly 75/25). Tirzepatide produces MORE total weight loss than semaglutide (SURMOUNT-1 showed −21% vs STEP-1 showed −15%), so the absolute amount of lean tissue lost is greater in absolute kilograms — but the percentage of weight that is lean tissue is comparable. The Coskun 2025 retatrutide body composition substudy (PMID 40609566) explicitly noted that the proportion of lean mass loss to weight loss with retatrutide was similar to other obesity treatments, including tirzepatide and semaglutide.
Bariatric surgery (Roux-en-Y gastric bypass, sleeve gastrectomy) historically produces a similar 70-80% fat / 20-30% lean ratio of total weight lost over 12-24 months. Tirzepatide at the 15 mg dose now produces total weight loss in the same range as sleeve gastrectomy (15-25%), and the body composition split is comparable. The clinical implication is that the lean tissue loss seen on tirzepatide is NOT a uniquely concerning drug effect — it is the standard physiology of rapid weight loss, whether the weight loss is driven by drug, surgery, very-low-calorie diet, or any other modality. Cava 2017 (PMID 28507015) concluded that diet-induced weight loss reduces muscle mass without hurting strength, and that high protein intake and resistance exercise help preserve it.
Three evidence-based interventions, in order of effect size: (1) resistance training 2-3 days per week with compound lifts (squat, hinge, push, pull, carry) — Murphy 2022 (PMID 34623696) showed that energy deficiency impairs lean mass gains from training, but training still attenuates lean mass loss in a deficit relative to no training; (2) enough protein, since no GLP-1-specific target exists; the Mechanick 2025 review (PMID 39295512) cites 1.2-1.5 g/kg a day for healthy people over 65 and up to 1.5 g/kg of ideal body weight after bariatric surgery; (3) avoid aggressive rate of loss — 0.5-1.0% of body weight per week is the target; faster rates (1.5-2.0%/week) disproportionately remove lean tissue. Cardio is helpful for cardiometabolic health but does not preserve muscle the way resistance training does.
No trial has set a protein target specific to GLP-1 therapy. The Mechanick 2025 review (PMID 39295512) lists the closest reference points: 0.8 g/kg a day for healthy people, 1.2-1.5 g/kg for healthy people over 65, and up to 1.5 g/kg of ideal body weight after bariatric surgery, adapted to the individual. For a 75 kg adult, 1.2-1.5 g/kg is roughly 90-113 g of protein per day, distributed as 25-40 g per meal across 3-4 daily meals. The practical challenge on tirzepatide is meeting this target on a suppressed appetite — many patients drop daily calories by 30-50% on tirzepatide without explicitly tracking protein and end up under-eating. Protein-first meal sequencing (eat protein before carbs and fats at each meal) helps when fullness comes early.
Partially — but the regain pattern after stopping a GLP-1 tends to favor fat over lean tissue. The SURMOUNT-4 trial (Aronne 2024, PMID 38078870) showed substantial weight regain after tirzepatide withdrawal, and the composition of regained weight in observational follow-up tends to be disproportionately fat mass. This is why active resistance training during AND after a tirzepatide cycle is the most important intervention. It tilts the body composition trajectory toward preserved or rebuilt lean tissue regardless of whether the drug is continued, and gives the best chance of regaining muscle if weight does come back.
For most healthy adults under 65, the proportional lean tissue loss on tirzepatide is not clinically dangerous — it tracks what any rapid weight loss produces, and improved insulin sensitivity plus reduced visceral and liver fat (documented in the SURPASS-3 MRI substudy, Cariou 2024, PMID 38528819) carry large net health benefit. The higher-risk groups are adults over 65 (already at risk of sarcopenia), patients with low baseline lean mass, perimenopausal women (estrogen decline accelerates sarcopenia independently), and patients with prior fragility fractures or osteoporosis. These groups should treat DXA monitoring, structured resistance training, and protein supplementation as standard rather than optional.
DXA scan at baseline and every 6 months is the gold standard — directly measures fat mass, lean tissue, and bone mineral content with ~1-2% precision. Bioelectrical impedance (BIA) scales like Withings, RENPHO, InBody, and Tanita are the next-best home option (~3-5% precision, with reasonable trend accuracy when measurement conditions are constant — same time of day, hydration state, empty bladder). Tape measurements at the upper arm, thigh, and waist combined with monthly photos in consistent lighting are the cheapest objective adjunct. The principle is consistency: pick one method, control the conditions, and track the trend over months rather than weeks.
No. The DailyMed prescribing information for Zepbound (tirzepatide for obesity) and Mounjaro (tirzepatide for type 2 diabetes) does NOT list muscle loss, sarcopenia, myopathy, or lean mass reduction as a labeled adverse reaction in Section 6 (Adverse Reactions). The body composition shifts during weight loss are characterized as a consequence of weight reduction rather than a direct drug pharmacological effect. The SURMOUNT-1 DXA substudy (Look 2025) is the primary peer-reviewed source clinicians reference for the magnitude of lean mass change during tirzepatide treatment.
No, and the "40 percent" figure is a common misreading of the body-composition data. In the SURMOUNT-1 body-composition sub-analysis and in pooled GLP-1 reviews, roughly 25 to 40 percent of total weight lost can come from lean mass (Mechanick 2025, PMID 39295512; Look 2025, PMID 39996356). That is lean mass as a fraction of the weight lost during the trial, not 40 percent of your entire muscle mass disappearing. Lean mass on a DEXA scan also includes water, glycogen, connective tissue, and organ mass, so not all of it is skeletal muscle. Tirzepatide has no direct toxic action on muscle fibers, and the proportion is modifiable: in trials where participants ate adequate protein and did resistance training during weight loss, the lean-mass share dropped considerably, with some trained, high-protein groups preserving or even gaining muscle while losing fat (Longland 2016, PMID 26817506).
Some investigational drug combinations are being studied to preserve or build muscle during incretin-driven weight loss, for instance pairing a GLP-1 or GLP-1/GIP drug with bimagrumab or other myostatin-pathway drugs. These are experimental, not FDA-approved for this purpose, and their long-term safety and benefit are unproven, so they are not part of standard care. For now, the established way to protect muscle on Mounjaro is adequate protein plus resistance training, not an additional medication. If you are interested in emerging options, discuss them only with your prescriber.

References

  1. 1.Look M, Dunn JP, Kushner RF, Cao D, Harris C, Gibble TH, Stefanski A, Griffin R. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes Obes Metab. 2025. PMID: 39996356.
  2. 2.Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A; SURMOUNT-1 Investigators. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022. PMID: 35658024.
  3. 3.Aronne LJ, Sattar N, Horn DB, Bays HE, Wharton S, Lin WY, Ahmad NN, Zhang S, Liao R, Bunck MC, Jouravskaya I, Murphy MA; SURMOUNT-4 Investigators. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024. PMID: 38078870.
  4. 4.Coskun T, Wu Q, Schloot NC, Haupt A, Milicevic Z, Khouli C, Harris C. Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial. Lancet Diabetes Endocrinol. 2025. PMID: 40609566.
  5. 5.Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF; STEP 1 Study Group. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021. PMID: 33567185.
  6. 6.Wadden TA, Bailey TS, Billings LK, Davies M, Frias JP, Koroleva A, Lingvay I, O'Neil PM, Rubino DM, Skovgaard D, Wallenstein SOR, Garvey WT; STEP 3 Investigators. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021. PMID: 33625476.
  7. 7.Cariou B, Linge J, Neeland IJ, Dahlqvist Leinhard O, Petersson M, Fernández Landó L, Bray R, Rodríguez Á. Effect of tirzepatide on body fat distribution pattern in people with type 2 diabetes. Diabetes Obes Metab. 2024. PMID: 38528819.
  8. 8.Stefanakis K, Kokkorakis M, Mantzoros CS. The impact of weight loss on fat-free mass, muscle, bone and hematopoiesis health: Implications for emerging pharmacotherapies aiming at fat reduction and lean mass preservation. Metabolism. 2024. PMID: 39481534.
  9. 9.Cava E, Yeat NC, Mittendorfer B. Preserving Healthy Muscle during Weight Loss. Adv Nutr. 2017. PMID: 28507015.
  10. 10.Murphy C, Koehler K. Energy deficiency impairs resistance training gains in lean mass but not strength: A meta-analysis and meta-regression. Scand J Med Sci Sports. 2022. PMID: 34623696.
  11. 11.Mechanick JI, Butsch WS, Christensen SM, et al. Strategies for minimizing muscle loss during use of incretin-mimetic drugs for treatment of obesity. Obes Rev. 2025. PMID: 39295512.
  12. 12.Longland TM, Oikawa SY, Mitchell CJ, et al. Higher compared with lower dietary protein during an energy deficit combined with intense exercise promotes greater lean mass gain and fat mass loss: a randomized trial. Am J Clin Nutr. 2016. PMID: 26817506.

Ozempic Muscle Loss & Lean Mass Protection: Honest Evidence Review

Muscle loss on Ozempic is real but proportional to weight-loss rate, not unique to the drug. SURMOUNT-1 DXA: about 25% of weight lost was lean tissue, the same share as on placebo. Resistance training 2-3x/week + 1.2-1.6 g/kg protein is the protective intervention.

13 min read

Can You Lose Weight on Semaglutide Without Exercise? Honest Evidence Review

Yes. STEP-1 reached -14.9% body weight at 68 weeks with diet counseling only — supervised exercise was not the intervention. The catch: without resistance training, roughly 25-40% of the weight you lose comes from lean tissue, not fat.

11 min read

Does Pilates Cause Weight Loss? Honest Evidence Review

Pilates does not produce clinically meaningful weight loss directly. Modest calorie burn and improvements in core strength + flexibility. Best paired with caloric deficit + resistance training.

17 min read

How to Break a Weight-Loss Plateau: Honest Evidence Review

Weight-loss plateaus are predictable physiology — adaptive thermogenesis pushes REE below predicted and NEAT declines unconsciously. Six evidence-graded interventions (diet break, protein, resistance training, sleep, TDEE math, GLP-1 dose change) break most in 2-4 weeks.

11 min read

How Quickly Does Tirzepatide Work for Weight Loss? Honest Evidence Review

Tirzepatide produces appetite suppression within 1-7 days and first scale movement by week 2-4. In SURMOUNT-1, 82% had lost 5% by week 12 (post hoc analysis) and the 15 mg arm averaged -20.9% at 72 weeks.

9 min read

When To Drink Protein Shakes For Weight Loss (Women)? Honest Evidence Review

No female-specific timing window in the published evidence. Schoenfeld 2013 meta (20 RCTs, 478 subjects): no timing effect when daily protein matched. Daily dose (1.6-2.2 g/kg) dominates; breakfast is the highest-leverage single placement.

11 min read

Where to get tirzepatide (Mounjaro / Zepbound) safely: vetted online providers

Vetted telehealth providers that prescribe online. We compare pricing, form, and states served.

No insurance needed · vetted by our editors

WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. How we make money

7.8

SnagRx

Compounded semaglutide and tirzepatide at a flat lifetime price

Read full review →

From $149/mo

Get started →
7.1

AgelessRx

Longevity-focused GLP-1 care with microdosing and brand-name options

Read full review →

From $209/mo

microdose, 2-month plan rate

Get started →
7.2

HumeCare+

GLP-1 weight loss with real-time body-composition tracking to protect muscle

Read full review →

From $299/mo

Get started →

About this analysis

Weight Loss Rankings is an independent editorial publication. Our provider dataset is verified directly against each provider's website and updated continuously. Read our full methodology →